European Journal of Pediatrics

, Volume 151, Supplement 1, pp S9–S12

New immunosuppressive drugs: Needs in and applications to pediatric transplantation

  • B. D. Kahan
Article

DOI: 10.1007/BF02125796

Cite this article as:
Kahan, B.D. Eur J Pediatr (1992) 151: S9. doi:10.1007/BF02125796

Abstract

The evolution of immunosuppressive therapy toward synergistic drug combinations seeks to minimize toxicity while potentiating efficacy. Median effect analysis discerns synergistic drug combinations that may be suitable for in vivo experiments in animals and for subsequent clinical trials. These studies suggest that two drugs rapamycin (RAPA) and brequinar (BQR) display synergistic effects in combination with cyclosporine. This combination must be evaluated for relative toxicity versus efficacy. Clinical trials to assess the individual toxicities of RAPA and BQR are presently underway in order to discern appropriate doses for randomized trials of clinical efficacy.

Key words

ImmunosuppressionDrug interactionsCyclosporine

Abbreviations

BMA

Behringwerke monoclonal antibody

BQR

brequinar

CI

combination index

CsA

cyclosporine

II

interleukin

MAb

monoclonal antibodies

NFAT

nuclear factor of activated T-cell

RAPA

rapamycin

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • B. D. Kahan
    • 1
  1. 1.Division of Immunology and Organ Transplant, Department of SurgeryThe University of Texas Medical School at HoustonHoustonUSA